These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 30987843

  • 1. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T.
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [Abstract] [Full Text] [Related]

  • 2. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 4. Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
    Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T.
    BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
    [Abstract] [Full Text] [Related]

  • 5. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, van Leeuwen FWB, van Leeuwen P, de Barros H, van der Poel H, Budäus L, Steuber T, Graefen M, Tennstedt P, Heck MM, Horn T, Maurer T.
    Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
    [Abstract] [Full Text] [Related]

  • 6. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    de Barros HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, Vis AN, Maurer T, van Leeuwen FWB, van der Poel HG, van Leeuwen PJ.
    Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
    [Abstract] [Full Text] [Related]

  • 7. [PSMA-radioguided surgery in localised recurrent prostate cancer].
    Horn T, Rauscher I, Eiber M, Gschwend JE, Maurer T.
    Urologe A; 2017 Nov; 56(11):1417-1423. PubMed ID: 29022058
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
    Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, Budäus L, Eiber M, Lunger L, Lischewski F, Heck MM, Maurer T.
    World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M, Christiansen H, Henkenberens C.
    BMC Cancer; 2020 Apr 29; 20(1):362. PubMed ID: 32349700
    [Abstract] [Full Text] [Related]

  • 10. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep 29; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 11. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.
    Eur Urol Focus; 2019 Jan 29; 5(1):50-53. PubMed ID: 30292421
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 29; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 13. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 14. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A, Farolfi A, Guenegou-Arnoux A, Romengas L, Scharl S, Fanti S, Serani F, Peeken JC, Katsahian S, Strouthos I, Ferentinos K, Koerber SA, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SK, Grosu AL, Ceci F, Henkenberens C, Kroeze SG, Guckenberger M, Belka C, Bartenstein P, Hruby G, Emmett L, Omerieh AA, Schmidt-Hegemann NS, Mose L, Aebersold DM, Zamboglou C, Wiegel T, Shelan M.
    JMIR Cancer; 2024 Sep 20; 10():e60323. PubMed ID: 39303279
    [Abstract] [Full Text] [Related]

  • 15. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug 20; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

  • 16. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
    Meijer D, van Leeuwen PJ, Donswijk ML, Boellaard TN, Schoots IG, van der Poel HG, Hendrikse HN, Oprea-Lager DE, Vis AN.
    BJU Int; 2022 Jan 20; 129(1):54-62. PubMed ID: 34028165
    [Abstract] [Full Text] [Related]

  • 17. [PSMA-Radioguided Surgery for Salvage Lymphadenectomy in Recurrent Prostate Cancer].
    Rauscher I, Eiber M, Maurer T.
    Aktuelle Urol; 2017 Apr 20; 48(2):148-152. PubMed ID: 28511221
    [Abstract] [Full Text] [Related]

  • 18. Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery.
    Knipper S, Lischewski F, Koehler D, Eiber M, van Leeuwen FWB, de Barros H, Berrens AC, Zuur L, van Leeuwen PJ, van der Poel H, Ambrosini F, Falkenbach F, Budäus L, Steuber T, Graefen M, Tennstedt P, Gschwend JE, Horn T, Heck MM, Maurer T.
    Eur Urol Oncol; 2024 May 09. PubMed ID: 38729805
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug 09; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 20. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN.
    Eur Urol Oncol; 2022 Apr 09; 5(2):146-152. PubMed ID: 35074282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.